Document Detail

Relation of change in apolipoprotein B/apolipoprotein A-I ratio to coronary plaque regression after Pravastatin treatment in patients with coronary artery disease.
MedLine Citation:
PMID:  20102908     Owner:  NLM     Status:  MEDLINE    
Some investigations have looked into the ability of measurements of apolipoprotein B/apolipoprotein A-I (apoB/apoA-I) ratio to predict cardiovascular events. We hypothesized that a decrease in the apoB/apoA-1 ratio by statin therapy would act on suppression of coronary plaque progression. A 6-month prospective study was conducted of 64 patients with coronary artery disease treated with pravastatin. The plaque volume, assessed by volumetric intravascular ultrasonography, had decreased significantly by 12.6% (p <0.0001 vs baseline). Although a significant decrease of 6.4% and 14.6% was found in the serum level of apoB and the apoB/apoA-1 ratio (p = 0.0001 and p <0.0001, respectively, vs baseline), a significant increase of 14.0% of and 12.0% in the level of apoA-I and apoA-II (both p <0.0001 vs baseline). No significant changes were found in the level of apoC-II or apoE. A stepwise regression analysis revealed that the change in the apoB/apoA-1 ratio was an independent predictor of the change in coronary plaque volume (beta coefficient 0.386; p = 0.0023). In conclusion, our results have indicated that the decrease in the apoB/apoA-I ratio is a simple predictor for coronary atherosclerotic regression: the lower the apoB/apoA-I ratio, the lower the risk of coronary atherosclerosis.
Shigemasa Tani; Ken Nagao; Takeo Anazawa; Hirofumi Kawamata; Shingo Furuya; Hiroshi Takahashi; Kiyoshi Iida; Michiaki Matsumoto; Takehiko Washio; Narimichi Kumabe; Atsushi Hirayama
Related Documents :
16450018 - Statin wars following coronary revascularization--evidence-based clinical practice?
16690338 - Beginning to end: cardiovascular implications of growth hormone (gh) deficiency and gh ...
7960248 - Lipoprotein(a) levels in patients with myocardial infarction treated with anistreplase:...
10980848 - Effect of lipid-lowering therapy on vasomotion and endothelial function.
17562528 - The effect of cardiac ischemic preconditioning on rat left ventricular gene expression ...
21613318 - Nicotine, cigarette smoking and cardiac arrhythmia: an overview.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The American journal of cardiology     Volume:  105     ISSN:  1879-1913     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2010 Jan 
Date Detail:
Created Date:  2010-01-27     Completed Date:  2010-02-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  144-8     Citation Subset:  AIM; IM    
Copyright Information:
Copyright 2010 Elsevier Inc. All rights reserved.
Department of Cardiology, Nihon University, Surugadai Hospital, Tokyo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Apolipoprotein A-I / blood*
Apolipoproteins B / blood*
Coronary Artery Disease / blood*,  drug therapy*,  ultrasonography
Follow-Up Studies
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Middle Aged
Pravastatin / therapeutic use*
Prospective Studies
Treatment Outcome
Ultrasonography, Interventional
Reg. No./Substance:
0/Apolipoprotein A-I; 0/Apolipoproteins B; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 81093-37-0/Pravastatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Quality of care and in-hospital outcomes in patients with coronary heart disease in rural and urban ...
Next Document:  Relation of coronary artery calcium score to premature coronary artery disease in survivors &gt;15 y...